General Information of This Antibody-drug Conjugate (ID: DRG0ANRPC)
ADC Name
JSKN021
Organization
Alphamab Oncology (Originator)
Drug Status
Phase 1
Drug-to-Antibody Ratio
6(4+2)
Antibody Name
Anti-EGFR/HER3 bsAb
 Antibody Info 
Antigen Name
Epidermal growth factor receptor (EGFR); Receptor tyrosine-protein kinase erbB-3 (HER3)
 Antigen Info 
Payload Name
MMAE; Alphatecan
 Payload Info 
Payload Target
DNA topoisomerase 1 (TOP1)+Microtubule (MT)
 Target Info 
Linker Name
A cleavable linker
 Linker Info 
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
Disease Name Phase 1 Phase 2 Phase 3 Approved
Unspecific solid tumor
1 Trials
Clinical trial identifier
NCT07617727; CTR20262023